Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms
暂无分享,去创建一个
S. Ascani | E. Sabattini | C. Tripodo | M. Ponzoni | A. Florena | V. Franco | U. Gianelli | A. Moro | L. Gugliotta | I. Cortinovis | E. Bonoldi | E. Boveri | A. Iurlo | G. F. Orcioni | R. Valli | A. Bossi
[1] T. Barbui,et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). , 2012, Blood.
[2] S. Bosari,et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis , 2012, Modern Pathology.
[3] M. Cazzola,et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. , 2012, Blood.
[4] T. Barbui,et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. , 2012, Blood.
[5] J. D. van der Walt,et al. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis , 2012, Haematologica.
[6] K. Hebeda,et al. Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia. , 2011, American journal of clinical pathology.
[7] T. Barbui,et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] E. Parot-Schinkel,et al. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis , 2010, Histopathology.
[9] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[10] A. Zanella,et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia. , 2008, American Journal of Clinical Pathology.
[11] U. Gianelli,et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. , 2008, Blood.
[12] C. Bloomfield,et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.
[13] Alessia Moro,et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoieticbone marrow histology , 2006, Leukemia & lymphoma.
[14] V. Diehl,et al. Initial (Latent) Polycythemia vera with Thrombocytosis Mimicking Essential Thrombocythemia , 2005, Acta Haematologica.
[15] H M Kvasnicka,et al. Standardization of bone marrow features--does it work in hematopathology for histological discrimination of different disease patterns? , 2005, Histology and histopathology.
[16] J. Thiele,et al. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients , 2003, Annals of Hematology.
[17] V. Diehl,et al. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) – a clinicopathological study , 1999, Leukemia.
[18] V. Diehl,et al. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. , 1996, Leukemia & lymphoma.
[19] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[20] B. Everitt,et al. Large sample standard errors of kappa and weighted kappa. , 1969 .
[21] M. Hyman. A necropsy tally board. , 1958, American journal of clinical pathology.
[22] J. Ferro,et al. Chronic myeloproliferative diseases. , 2014, Handbook of clinical neurology.
[23] Peter J Campbell,et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. , 2008, Blood.
[24] J. D. van der Walt,et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.
[25] Ada Maria Florena,et al. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. , 2004, Haematologica.
[26] H M Kvasnicka,et al. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. , 2000, Haematologica.